Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis

Image: Arcutis plans to make ZORYVE foam widely available by the end of January next year. Credit: Arcutis Biotherapeutics via Globenewswire.



  • Arcutis Biotherapeutics